LOXL3 and metastatic melanoma: Moreover, examination of published melanoma transcriptomic profiles [25, 26] and TCGA data [24] for LOXL3 expression confirmed a significant upregulation of LOXL3 levels in both primary and metastatic melanoma patient-derived samples compared to controls (Fig. 1c, d), while no differences in expression were found between primary and metastatic samples (Fig. 1c, d; Supplementary Fig. 1a).